Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (101-110 of 267) with videos related to

Pageof 27
Sort By:
AIDS (London, England)|May 13, 2006
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patientsStéphanie Dominguez, Jade Ghosn, Marc-Antoine Valantin, et al.
Emergencias : Revista De La Sociedad Espanola De Medicina De Emergencias|January 26, 2021
Characteristics of human immunodeficiency virus exposure and predictors of time until access to postexposure prophylaxis: a prospective observational studyEnrique Casalino, Donia Bouzid, Stephanie Antoniol, et al.
HIV Medicine|August 18, 2009
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trialJade Ghosn, P Flandre, I Cohen-Codar, et al.
Sexually Transmitted Infections|September 4, 2020
Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in ParisValentina Isernia, Bao Phung, Annie Marie Lepretre, et al.
The Journal of Antimicrobial Chemotherapy|November 6, 2021
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertionsQuentin Le Hingrat, Gilles Collin, Florence Damond, et al.
AIDS (London, England)|March 3, 2006
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of timeJade Ghosn, Isabelle Pellegrin, Cécile Goujard, et al.
AIDS (London, England)|September 9, 2004
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected menJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genesKatherine A Sutherland, Jean L Mbisa, Jade Ghosn, et al.
Blood|September 28, 2013
Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individualsChristina Psomas, Jean-Philippe Lavigne, Claudine Barbuat, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2010
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trialVéronique Avettand-Fenoel, Philippe Flandre, Marie-Laure Chaix, et al.
Pageof 27

Showing results (101-110 of 267) with videos related to

Sort By:
Pageof 27
AIDS (London, England)|May 13, 2006
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patientsStéphanie Dominguez, Jade Ghosn, Marc-Antoine Valantin, et al.
Emergencias : Revista De La Sociedad Espanola De Medicina De Emergencias|January 26, 2021
Characteristics of human immunodeficiency virus exposure and predictors of time until access to postexposure prophylaxis: a prospective observational studyEnrique Casalino, Donia Bouzid, Stephanie Antoniol, et al.
HIV Medicine|August 18, 2009
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trialJade Ghosn, P Flandre, I Cohen-Codar, et al.
Sexually Transmitted Infections|September 4, 2020
Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in ParisValentina Isernia, Bao Phung, Annie Marie Lepretre, et al.
The Journal of Antimicrobial Chemotherapy|November 6, 2021
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertionsQuentin Le Hingrat, Gilles Collin, Florence Damond, et al.
AIDS (London, England)|March 3, 2006
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of timeJade Ghosn, Isabelle Pellegrin, Cécile Goujard, et al.
AIDS (London, England)|September 9, 2004
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected menJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genesKatherine A Sutherland, Jean L Mbisa, Jade Ghosn, et al.
Blood|September 28, 2013
Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individualsChristina Psomas, Jean-Philippe Lavigne, Claudine Barbuat, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2010
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trialVéronique Avettand-Fenoel, Philippe Flandre, Marie-Laure Chaix, et al.
Pageof 27